Saturday 17 October 2026
Export GANX’s income statement to Excel — free account
Gain Therapeutics, Inc.
GANX Healthcare Biotechnology
Gain Therapeutics, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $55,200.00, down 60.6% from fiscal 2022. In the quarter to June 2026, EPS grew 42.1%, free cash flow grew 8.22% and total debt fell 23.9%, each against the same quarter a year earlier.
1.26
0.07
−5.26%
Follow GANX
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(261.72%) | (155.66%) | (214.69%) | (268.30%) | |
| (153.07%) | (115.40%) | (139.91%) | (159.22%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(301.48%) | (106.34%) | (147.61%) | (173.59%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(0.49) | (0.56) | (0.46) | (0.44) | |
Free Cash Flow |
(17.30) | (18.47) | (19.37) | (18.95) | |
| Other line items | |||||
Cash ROIC |
(114.27%) | (46.39%) | (62.65%) | (76.67%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.07 | 0.04 | 0.05 | 0.05 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.89 | 0.92 | 0.91 | 0.94 | |
Depreciation/Fixed assets |
1.02 | 1.26 | 1.74 | 2.12 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.49) | (0.56) | (0.46) | (0.44) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates